Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 26, 2021

View Archived Issues

Phase I trial evaluates [11C]YJH-08 PET imaging of GR expression in metastatic prostate cancer

Camino studies SBP-9330 in first-in-human trial for smoking cessation

New Toll-like receptor 7 agonists identified at Bristol Myers Squibb

Vertex Pharmaceuticals presents new apolipoprotein L1 inhibitors

New CREB-2 inhibitors discovered at Evotec International

Memorial Sloan-Kettering Cancer Center describes prodrugs useful in adoptive cell therapy

Mutational profiling gives clues to development, new puzzles about disease

Blade receives IND clearance for phase I study of cudetaxestat for IPF

Data presented for Almirall's JAK inhibitor LAS-200019

Janssen targets DHODH with new compounds for acute myelogenous leukemia

HUTCHMED begins phase Ib/II study of fruquintinib with tislelizumab in TNBC and endometrial cancer

New phase I/II trial investigates RVU-120 in relapsed/refractory metastatic or advanced solid tumors

CPI-613 advances into phase II evaluation in biliary tract cancer

Phase II trial of izokibep in ankylosing spondylitis commences dosing

Epeleuton shows promise in hamster model for SARS-CoV-2 infection

Mutation in RAPGEF1 gene tied to global developmental delay syndrome

Phase II study of SHR-0302 in alopecia areata meets primary efficacy endpoint

Studies reveal efficacy and mechanism of SARS-CoV-2-neutralizing antibody SC-31

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...